Back to VE Van Eck Associates Corp

REGNREGN

Showing 8 of 28 quarters

Position history for VEVan Eck Associates Corp's holdings in Regeneron Pharmaceuticals, Inc.

Yes. Van Eck Associates holds 71,402 shares of REGN (Regeneron Pharmaceuticals), worth $54.1M, as of its Q3 2026 13F filing. It increased the position by 6,070 shares (+9.3%) from Q2 2026. Van Eck Associates has listed REGN in each of its last 28 quarterly 13F filings.

Current Value

$54.1M

Current Shares

71,402

Total Value Change

+$12.4M

Total Shares Change

+12,869

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q3
Latest
Increased
71,402
+9.3%
$54.1M0.0%$758.27
32
2026-Q2
Increased
65,332
+4.4%
$40.7M0.0%$622.81
30
2026-Q1
Decreased
62,584
-3.6%
$48.4M0.0%$770.59
0
2025-Q4
Increased
64,895
+14.8%
$50.1M0.0%$768.90
34
2025-Q3
Decreased
56,518
0.0%
$31.8M0.0%$559.40
0
2025-Q2
Increased
56,519
+2.3%
$29.7M0.0%$521.53
29
2025-Q1
Decreased
55,227
-5.7%
$35M0.0%$629.11
0
2024-Q4
Increased
58,533
+0.7%
$41.7M0.1%$705.67
29

Optional analytics helps us improve. How it’s used